Entering text into the input field will update the search result below

AbbVie reports SAPPHIRE-I HCV results

Nov. 18, 2013 9:05 AM ETAbbVie Inc. (ABBV) StockABBV, ENTABy: Colin Lokey, SA News Editor
  • AbbVie (NYSE:ABBV) is out with data from SAPPHIRE-I (that's the first of six 3D Phase 3 GT1 HCV trials).
  • SVR12 rates: 95% in GT1a and 98% in GT1b.
  • Regulatory submissions expected in Q2 of next year. (PR)
  • Worth watching on the news: Enanta (NASDAQ:ENTA), which discovered one of the regimen's components (ABT-450) as part of an ongoing collaboration with ABBV.

Recommended For You

More Trending News

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.